{
  "scenario_id": "biotechnology_gene_therapy_investment_decision_2025",
  "context": "Mid-sized biotechnology company with 150 employees, developing gene therapy for rare genetic disorders, seeking $50M Series C funding",
  "stakeholders": {
    "requester": "CEO",
    "approvers": ["Board of Directors", "Lead Investors"],
    "influencers": ["Chief Scientific Officer", "Chief Medical Officer", "Regulatory Affairs Head", "IP Counsel"]
  },
  "request": {
    "amount": "$50,000,000",
    "purpose": "Fund Phase 2 clinical trials and manufacturing scale-up for gene therapy platform",
    "urgency": "high",
    "justification": "Strong preclinical data showing 80% efficacy in animal models, orphan drug designation secured, potential $2B market opportunity"
  },
  "decision_process": [
    {
      "stage": "due_diligence",
      "duration": "6 weeks",
      "activities": ["Scientific data review", "Regulatory pathway assessment", "IP portfolio evaluation", "Market analysis"],
      "outcome": "Positive due diligence results"
    },
    {
      "stage": "board_review",
      "duration": "2 weeks",
      "activities": ["Financial modeling review", "Risk assessment", "Strategic alignment evaluation"],
      "outcome": "Approved for investor presentations"
    },
    {
      "stage": "investor_negotiations",
      "duration": "8 weeks",
      "activities": ["Term sheet negotiations", "Valuation discussions", "Due diligence defense", "Legal documentation"],
      "outcome": "Funding secured with favorable terms"
    }
  ],
  "business_impact": {
    "expected_patients_treated": 5000,
    "projected_revenue": "$500,000,000",
    "risk_factors": ["Clinical trial failures", "Regulatory setbacks", "Manufacturing challenges", "Competitive landscape changes"]
  }
}